Curative efficacy of buyang huanwu decoction in treating patients with Takayasu arteritis at active stage and its improvement on vascular endothelial injury / 中国生化药物杂志

ABSTRACT

Objective To investigate the curative efficacy of buyang huanwu decoction in combination with cyclophosphamide in treating patients with Takayasu arteritis(TA)at active stage and its improvement on vascular endothelial injury.Methods 88 patients with TA at active stage who received therapy in The Hospital of Beijing Armed Police Corps from January 2015 to April 2016 were selected as research objects.According to therapeutic schemes,those patients were divided into the control group(n=42)and the observation group(n=46).The control group was given cyclophosphamide,while the observation group was given cyclophosphamide in combination with buyang huanwu decoction.Then,the total therapeutic efficacy ratio,laboratory-related indices and indices of vascular endothelial injury were compared between the two groups.During the treatment,incidence of adverse reactions were compared.Results The observation group had a total therapeutic efficacy ratio of 89.1％,which was statistically higher than that of 71.4％in the control group(P<0.05).After the treatment,in comparison with the control group,laboratory-related indices of erythrocyte sedimentation rate(ESR),C reactive protein(CRP)and vascular endothelial injury indices of vascular endothelial growth factor(VEGF),endothelin-1(ET-1)in the observation group were statistically lower(all P<0.05).During the treatment,the incidence of adverse reactions in the observation group was 26.1％,which was statistically same with that of 21.4％in the control group.Conclusion Cyclophosphamide in combination with buyang huanwu decoction is effective for patients with TA at active stage with a high total therapeutic efficacy ratio.And it can significantly improve laboratory-related indices and vascular endothelial injury without increasing incidence of adverse reactions.